8.09 +0.05 (0.62%)
After hours: 7:52PM EDT
|Bid||8.04 x 1200|
|Ask||8.09 x 4000|
|Day's Range||7.83 - 8.17|
|52 Week Range||6.07 - 25.13|
|Beta (3Y Monthly)||2.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.78|
Purdue Pharma filed for chapter 11 bankruptcy today after reaching a tentative deal with 24 state attorneys general that accused the company of fueling the opioid crisis. Yahoo Finance's Ines Ferre joins Akiko Fujita on 'The Ticker' to discuss.
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $8.04, moving +1.26% from the previous trading session.
This week, we saw Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) make a big move in the cannabis industry, through a distribution deal between its subsidiary Salomon, Levin, Elstein, and InterCure Ltd ...
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Apple, American Express, Kraft Heinz and Teva Pharmaceutical
Cannabis companies have been feverishly stitching up partnerships with each other, beverage companies and biopharma companies to tap into the market's huge potential. Israel-based Teva Pharmaceutical Industries ...
HERZLIYA, Israel, Sept. 13, 2019 /PRNewswire/ -- InterCure (INCR.TA), announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries (NYSE: and TASE: TEVA). Under terms of the agreement, S.L.E. will distribute Canndoc's GMP products to pharma clients, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel, including pharmacy chains. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndoc's products to countries that support regulations for the sale and distribution of cannabis products for medical use.
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
(Bloomberg) -- Bearish bets against some of the top suppliers of opioid painkillers are paying off big as their stocks plunge on the potential of a costly reckoning for their role in fueling an epidemic of addiction to the drugs.Short-sellers in Mallinckrodt Plc, Endo International Plc and Teva Pharmaceutical Industries Ltd., which are among the most exposed to opioid litigation, have pocketed $880 million since May 1, according to data from financial analytics firm S3 Partners. Shares of the three companies have lost between 67% and 95% in the last year as Wall Street attempts to quantify the billions of dollars in liabilities they could face and bankruptcy concerns mount.Bearish bets against Mallinckrodt have been the most profitable. Short-sellers have cleared $495 million since the start of May, when activity “started getting very active,” Ihor Dusaniwsky, S3’s head of research said by email. It was also right after new details of Mallinckrodt’s dispute with the Centers for Medicare and Medicaid Services over rebates for its top-selling drug Acthar emerged.Mallinckrodt’s shares have since plunged to less than $2 from more than $15. A Bloomberg report on Wednesday that the company had hired a restructuring firm to advise on options sparked concerns from analysts that a bankruptcy filing could be imminent.Teva and Endo have troubles of their own beyond the opioid crisis as the copycat drugmakers are also named in litigation alleging that they colluded to fix prices for generic drugs. Endo bears are up $123 million since the beginning of May, while Teva shorts have reaped $262 million in mark-to-market profits, according to S3 data.While Mallinckrodt shares on Friday were clawing back some of Thursday’s 39% plunge, they were still down about 95% from a year ago. The company should be able to meet obligations on $700 million in debt coming due in April 2020, it’s the outcome of the ongoing opioid suits that’s the “wild-card” putting Mallinckrodt “in a precarious position,” SVB Leerink analyst Ami Fadia told clients in a note. She cut her price target to $2 from $7.To contact the reporters on this story: Cristin Flanagan in New York at firstname.lastname@example.org;Bailey Lipschultz in New York at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
Mallinckrodt stock plummeted Thursday on a report the pharmaceutical company could restructure to contend with legal action stemming from the opioid crisis. Teva and Endo stocks also fell.
Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?
A judge ruled late Tuesday to include generic drugmakers like Teva and Endo in a sweeping lawsuit regarding the opioid epidemic. Plaintiffs say drugmakers used deceptive marketing.
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migr
Across the United States, there are thousands of civil cases, mostly in state courts, represented by state prosecutors to compensate families who have been hurt by the opioid epidemic. The plaintiffs in these cases are accusing drug manufacturers of actively marketing addictive drugs and pharmaceutical distributors of failing to detect or report suspicious opioid orders. Many of the defendants in these cases are generic drug manufacturers, pharmaceutical distributors, and retail pharmacies that we cover.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that the U.S. Department of Commerce has selected Brendan O’Grady, Executive Vice President and Head of North America Commercial to serve on the U.S. Investment Advisory Council. The Council is a 25-member panel of national experts who will counsel and advise Secretary of Commerce Wilbur Ross on attracting and retaining foreign direct investment in the U.S. O’Grady’s appointment reflects recognition of his deep expertise spanning more than 28 years in the pharmaceutical industry.
Bayer has lost nearly the entire value of its 2018 Monsanto purchase. Teva has already lost more than the entire value of its Actavis Generics purchase. Did antitrust regulators see that coming? Continue reading...
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.